LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

Search

Anavex Life Sciences Corp

Chiusa

SettoreSettore sanitario

8.6 7.37

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

8.01

Massimo

8.61

Metriche Chiave

By Trading Economics

Entrata

915K

-11M

EPS

-0.132

Dipendenti

42

EBITDA

-779K

-13M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+254.92% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-21M

706M

Apertura precedente

1.23

Chiusura precedente

8.6

Notizie sul Sentiment di mercato

By Acuity

50%

50%

164 / 381 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Anavex Life Sciences Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 giu 2025, 22:33 UTC

Acquisizioni, Fusioni, Takeovers

KKR to Acquire Australian Power Provider Zenith Energy

16 giu 2025, 21:55 UTC

I principali Market Mover

Geospace Technologies Shares Up on Petrobras Pact

16 giu 2025, 17:04 UTC

I principali Market Mover

Roku Shares Climb on Advertising Deal with Amazon

16 giu 2025, 23:51 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

16 giu 2025, 23:51 UTC

Discorsi di Mercato

Nikkei May Trade Range Bound Amid Israel-Iran Conflict -- Market Talk

16 giu 2025, 23:41 UTC

Discorsi di Mercato

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

16 giu 2025, 23:10 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

XRG Has 'Viable Path' to Approval of Santos Takeover -- Market Talk

16 giu 2025, 23:02 UTC

Discorsi di Mercato

Auckland Airport Unlikely to Hit Target for International Passengers -- Market Talk

16 giu 2025, 22:32 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Santos Unlikely to Attract Rival Bidder to XRG -- Market Talk

16 giu 2025, 22:03 UTC

Acquisizioni, Fusioni, Takeovers

KKR & Co. to Buy Zenith Energy From Consortium Including Pacific Equity Partners, OPSEU Pension Trust, Foresight Group >KKR

16 giu 2025, 22:00 UTC

Acquisizioni, Fusioni, Takeovers

KKR Acquires Leading Australian Independent Power Producer Zenith Energy >KKR

16 giu 2025, 21:56 UTC

Utili

Lennar Has an Earnings Miss. The Stock Slips. -- Barrons.com

16 giu 2025, 21:10 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi in Talks to Sign $8 Billion Deal With Gas Producer Aethon -- WSJ

16 giu 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

16 giu 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

16 giu 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

16 giu 2025, 20:49 UTC

Discorsi di Mercato

Fitch Revises Canadian Provinces Fiscal Outlook to 'Deteriorating' -- Market Talk

16 giu 2025, 20:14 UTC

Acquisizioni, Fusioni, Takeovers

Update: EchoStar Stock Surges. It's Short Covering and President Trump. -- Barrons.com

16 giu 2025, 20:13 UTC

Discorsi di Mercato

Natural Gas Gains on Warmer Outlook -- Market Talk

16 giu 2025, 19:58 UTC

Acquisizioni, Fusioni, Takeovers

OpenAI and Microsoft Tensions Are Reaching a Boiling Point -- WSJ

16 giu 2025, 19:13 UTC

Discorsi di Mercato

Middle-East Conflict May Not Push Up Oil Long Term -- Market Talk

16 giu 2025, 19:09 UTC

Discorsi di Mercato

Amazon-Roku Deal Shows Competition for Streaming Ad Space -- Market Talk

16 giu 2025, 18:43 UTC

Discorsi di Mercato

May Could Mark Nascent Recovery in Canada Housing Market -- Market Talk

16 giu 2025, 18:36 UTC

Discorsi di Mercato

Soybeans May Get Boost from Renewable Fuel Obligations -- Market Talk

16 giu 2025, 18:29 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

16 giu 2025, 18:29 UTC

Discorsi di Mercato

Shopify Appears More Resilient Than Feared -- Market Talk

16 giu 2025, 18:22 UTC

Discorsi di Mercato

Citi Forecasts Downturn in Gold Futures -- Market Talk

16 giu 2025, 16:42 UTC

Discorsi di Mercato

Homebuyers' Downpayments Are Shrinking For First Time in 2 Years -- Market Talk

16 giu 2025, 16:37 UTC

Discorsi di Mercato

Big, Beautiful Bill Might Not Mean Big Growth -- Market Talk

16 giu 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Anavex Life Sciences Corp Previsione

Obiettivo di Prezzo

By TipRanks

254.92% in crescita

Previsioni per 12 mesi

Media 28.5 USD  254.92%

Alto 42 USD

Basso 15 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Anavex Life Sciences Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

2

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

8.275 / 9.312Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

164 / 381 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.